Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?
Open Access
- 30 June 2013
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 12 (8), 835-838
- https://doi.org/10.1016/j.autrev.2012.11.009
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 yearArthritis Care & Research, 2012
- Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisalsRheumatology, 2011
- Disease activity and low physical activity associate with number of hospital admissions and length of hospitalisation in patients with rheumatoid arthritisArthritis Research & Therapy, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals Of The Rheumatic Diseases, 2010
- Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish settingRheumatology, 2010
- Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trialArthritis Research & Therapy, 2010
- UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drugCurrent Medical Research and Opinion, 2008
- Low‐dose prednisolone in addition to the initial disease‐modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two‐year randomized trialArthritis & Rheumatism, 2005
- An Overview of Economic Evaluations for Drugs Used in Rheumatoid ArthritisDrugs, 2005